The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online
doi:10.1084/jem.2045iti2
The Journal of Experimental Medicine, Vol. 204, No. 5, 967a-
The Rockefeller University Press, 0022-1007 $30.00
© Bashyam
This Article
Right arrow Full Text (PDF, 1551K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bashyam, H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bashyam, H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

IN THIS ISSUE

Breast cancer hijacks dendritic cells


Figure 1
Breast tumor size increases when DCs and T cells team up (red).

On page 1037, Aspord et al. find that immune cells are swayed to the dark side by cancerous forces. Instead of priming a killing response, dendritic cells (DCs) that infiltrate breast tumors actually help the tumor grow.

The group previously found that human breast tumors often include a large number of mature dendritic cells that form clusters with CD4+ T cells. This association suggested that immunity was at work in the tumor, but it also hinted at an oddity: mature DCs are normally found in lymph nodes, not the affected tissue.

To figure out what these DCs were doing in the tumors, Aspord and colleagues studied humanized mice that were grafted with human breast cancer cell lines. In these mice, the DCs recruited CD4+ T cells to the tumors but did not prime an antitumor immune response. Instead, the DCs instigated the T cells to secrete IL-13 and thereby promote tumor growth.

IL-13 helped tumors by activating a signaling pathway that has been implicated in metastasis. But why the DCs initiated this tumor-friendly response is still unclear.

The findings might help explain why DC-based vaccine therapies sometimes fail in clinical trials. The team now plans to test IL-13 antagonists in breast cancer patients in combination with candidate DC vaccines. The hope is that the antagonists will prevent the vaccine-induced antitumor immunity from being subverted into a cancer-promoting response. Formula



Hema Bashyam

hbashyam{at}rockefeller.edu


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Full Text (PDF, 1551K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bashyam, H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bashyam, H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?


  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS